Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Infinity Extends R&D Collaboration With Mundipharma, Gets Another $50 Million For PI3K Program

This article was originally published in The Pink Sheet Daily

Executive Summary

Mundipharma has once again reinforced its partnership with Infinity by committing an additional $50 million to the partnership, with the money to be used in 2013 to support the biotech’s ongoing development of Hedgehog pathway inhibitor IPI-926.

Advertisement

Related Content

Raman Singh Of Mundipharma Sets Sights On Emerging Markets: An Interview With PharmAsia News (Part 2 of 2)
Raman Singh Of Mundipharma Sets Sights On Emerging Markets: An Interview With PharmAsia News (Part 1 of 2)
Raman Singh Of Mundipharma Sets Sights On Emerging Markets: An Interview With PharmAsia News (Part 1 of 2)
Infinity Regains Pipeline Rights, Gives Up Equity In Rejiggered Purdue Alliance
Gilead Springs Further Into Oncology With Calistoga Acquisition
Infinity In-Licenses Portfolio Of PI3 Kinase Inhibitors For Inflammatory Diseases
Infinity/Purdue: The Challenge of Reprising Roche/Genentech
With Innovative Purdue Deal, Infinity Finds Shelter From The Storm

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

PS073099

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel